Acute Ischemic Stroke Clinical Trial
Official title:
Safety and Efficacy of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis for Acute Ischemic Stroke: A Multicenter, Randomized, Parallel-controlled Clinical Trial
NCT number | NCT04980625 |
Other study ID # | SERIC-IVT |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2021 |
Est. completion date | May 11, 2023 |
Verified date | March 2024 |
Source | The First Hospital of Jilin University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.
Status | Completed |
Enrollment | 558 |
Est. completion date | May 11, 2023 |
Est. primary completion date | May 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1) Age=18 years, regardless of sex; - 2) Patients with a clinically definite diagnosis of acute ischemic stroke and undergo intravenous thrombolysis with alteplase; - 3) Baseline NIHSS >= 4, and <= 24; - 4) Baseline mRS 0-1; - 5) Signed and dated informed consent is obtained; Exclusion Criteria: - 1) Patients who have the contraindication of intravenous thrombolysis with alteplase. - 2) The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc. - 3) Pregnant or lactating women. - 4) Previous remote ischemic conditioning therapy or similar treatment; - 5) Severe hepatic and renal dysfunction. - 6) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons. - 7) Unwilling to be followed up or treated for poor compliance. - 8) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission. - 9) Other conditions that the researchers think are not suitable for the group. |
Country | Name | City | State |
---|---|---|---|
China | The First Hospital of Jilin University | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Yi Yang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | 24 hours, 7 days, 30±3 days, 90±3 days | |
Other | heart rate at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | heart rate at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | 24 hours, 7 days, 30±3 days, 90±3 days | |
Other | Numeric rating scales (NRS) score during intervention. | Numeric rating scales (NRS) score during intervention. Ranged from 0 to 10, a low value represents a less pain. | 7 days | |
Other | The number of early withdrawal for safety or tolerability reasons | The number of early withdrawal for safety or tolerability reasons | 7 days | |
Primary | Proportion of patients with Modified Rankin Scale (mRS) Score 0-1 | Proportion of patients with Modified Rankin Scale (mRS) Score 0-1. Ranged from 0 to 6, a low value represents a better outcome. | 3 months | |
Secondary | National Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | National Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. Ranged from 0 to 42, a low value represents a better outcome. | 24 hours, 7 days, 30±3 days, 90±3 days | |
Secondary | Barthel Index (BI) at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | Barthel Index (BI) at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. Ranged from 0 to 100, a high value represents a better outcome. | 24 hours, 7 days, 30±3 days, 90±3 days | |
Secondary | modified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | modified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. Ranged from 0 to 6, a low value represents a better outcome. | 24 hours, 7 days, 30±3 days, 90±3 days | |
Secondary | Proportion of patients with modified Rankin Scale (mRS) Score 0-2, NIHSS score 0-1, Barthel Index (BI) =95 at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. | Proportion of patients with modified Rankin Scale (mRS) Score 0-2, NIHSS score 0-1, Barthel Index (BI) =95 at 24 hours, 7 days, 30±3 days, 90±3 days after IVT. mRS: Ranged from 0 to 100, a high value represents a better outcome. NIHSS: Ranged from 0 to 42, a low value represents a better outcome. BI: Ranged from 0 to 100, a high value represents a better outcome. | 24 hours, 7 days, 30±3 days, 90±3 days | |
Secondary | Frequency of adverse events during follow-up | Severe adverse events through day-90 after the onset of acute ischemic stroke. | 90 days | |
Secondary | Frequency of Hemorrhagic transformation during hospitalization | Frequency of Hemorrhagic transformation during hospitalization | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 | |
Completed |
NCT01021319 -
Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)
|